77225-89-9

Basic information

• Product Name: L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester
• Synonyms: (S)-3-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-propionic acid tert-butyl ester;Boc-Dap(Cbz)-OtBu;tert-butyl 2-[(S)-(tert-butoxycarbonyl)amino]-3-[(carbobenzoxy)amino]propionate
• CAS NO: 77225-89-9
• Molecular Formula: C20H30N2O6
• Molecular Weight: 394.468
• Mol File: 77225-89-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(77225-89-9)
• EPA Substance Registry System: L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[(phenylmethoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(77225-89-9)

Safety Data

• Hazardous Substances Data: 77225-89-9(Hazardous Substances Data)

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 77255-62-0 tert-butyl 3-N-carbobenzoxy-(S)-2,3-diaminopropionate 
• 7536-55-2 N-tert-butyloxycarbonylasparagine 
• 76387-70-7 (S)-3-amino-2-tert-butoxycarbonylaminopropionic acid 
• 65710-57-8 3-{[(benzyloxy)carbonyl]amino}-N-(tert-butoxycarbonyl)-L-alanine 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 918906-33-9 C₂₉H₄₄BrN₅O₁₀S 
• 77215-54-4 tert-butyl 2-<(tert-butoxycarbonyl)amino>-3-aminopropanoate 

Relevant articles and documents

THERAPEUTIC COMPOUNDS AND METHODS

Disclosed herein are compounds of formula I: (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 may any of the values defined herein, as well as compositions comprising such compounds. Also disclosed are methods for treating diseases including neurodegenerative disorders such as Parkinson's Disease and Alzheimer's Disease.

Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs

Plethoras of CNS-active drugs fail to effect their pharmacologic response due to their in vivo inability to cross the blood-brain barrier (BBB). The classical prodrug approach to overcome this frailty involves lipophilic derivatives of the polar drug, but we herein report a novel approach by which endogenous transporters at BBB are exploited for brain drug delivery. The crucial role played by glutathione in pathogenesis of Parkinson's and the presence of its influx transporters at the basolateral membrane of BBB served as the basis for our anti-Parkinson prodrug design strategy. A metabolically stable analogue of glutathione is used as a carrier for delivery of dopamine and adamantamine. An account of successful syntheses of these prodrugs along with their transport characteristics and stability determination is discussed.

Potential inhibitors of l-asparagine biosynthesis. 5. Electrophilic amide analogues of (S)-2,3-diaminopropionic acid

-